Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Effectiveness of Alpelisib + Fulvestrant Compared With Real-World Standard Treatment Among Patients With HR+, HER2−, PIK3CA-Mutated Breast CancerOncologist 2021 Apr 28;[EPub Ahead of Print], S Turner, S Chia, H Kanakamedala, WC Hsu, J Park, D Chandiwana, A Ridolfi, CL Yu, JP Zarate, HS Rugo
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.